NCI approves John Theurer Cancer Center as research consortium member

John Theurer Cancer Center at Hackensack University Medical Center announced it received approval from the National Cancer Institute as a research consortium member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center Consortium. The CEO of Hackensack Meridian Health, Robert C. Garrett, led the press conference, which was attended by more than 200 people, including New Jersey Lt. Governor Sheila Oliver. The John Theurer Cancer Center is now a member of one of just 16 NCI-recognized cancer consortia based at the nation’s most prestigious institutions including Harvard University, Dana-Farber/ Harvard Cancer Center; Cleveland Clinic, part of the NCI-designated Case Comprehensive Cancer Center and the Mayo Clinic Cancer Center. John Theurer Cancer Center’s collaboration with NCI-designated Georgetown Lombardi Comprehensive Cancer Center enables both organizations to continue their research at the highest level to deliver tomorrow’s breakthroughs in cancer cures today. The consortium plans to advance research and innovate treatment in four key areas: Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology. (This article was published on PR Newswire and was picked up by more than 155 outlets, including New Jersey Business Magazine, OncLive, Business Insider: Markets Insider, MarketWatch, ABC7 and MenaFN with a potential audience of 61,989,311.